- Home
- QURE vs EYPT Comparison
QURE vs EYPT Comparison
Compare QURE & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- EYPT
- Stock Information
- Founded
- QURE 1998
- EYPT 1987
- Country
- QURE Netherlands
- EYPT United States
- Employees
- QURE N/A
- EYPT N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- QURE Health Care
- EYPT Industrials
- Exchange
- QURE Nasdaq
- EYPT Nasdaq
- Market Cap
- QURE 866.3M
- EYPT 967.4M
- IPO Year
- QURE 2007
- EYPT 2005
- Fundamental
- Price
- QURE $70.00
- EYPT $12.25
- Analyst Decision
- QURE Strong Buy
- EYPT Strong Buy
- Analyst Count
- QURE 12
- EYPT 5
- Target Price
- QURE $69.67
- EYPT $27.40
- AVG Volume (30 Days)
- QURE 2.6M
- EYPT 1.4M
- Earning Date
- QURE 10-29-2025
- EYPT 10-31-2025
- Dividend Yield
- QURE N/A
- EYPT N/A
- EPS Growth
- QURE N/A
- EYPT N/A
- EPS
- QURE N/A
- EYPT N/A
- Revenue
- QURE $14,337,000.00
- EYPT $51,898,000.00
- Revenue This Year
- QURE N/A
- EYPT N/A
- Revenue Next Year
- QURE $229.18
- EYPT N/A
- P/E Ratio
- QURE N/A
- EYPT N/A
- Revenue Growth
- QURE N/A
- EYPT 2.99
- 52 Week Low
- QURE $5.35
- EYPT $3.91
- 52 Week High
- QURE $71.50
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- QURE 71.31
- EYPT 47.68
- Support Level
- QURE $58.05
- EYPT $11.15
- Resistance Level
- QURE $64.75
- EYPT $12.21
- Average True Range (ATR)
- QURE 4.18
- EYPT 0.70
- MACD
- QURE -0.71
- EYPT -0.10
- Stochastic Oscillator
- QURE 89.18
- EYPT 34.32
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.